DrugPatentWatch Database Preview
DAURISMO Drug Profile
Which patents cover Daurismo, and what generic alternatives are available?
Daurismo is a drug marketed by Pfizer Inc and is included in one NDA. There are two patents protecting this drug.
This drug has forty-nine patent family members in forty-one countries.
The generic ingredient in DAURISMO is glasdegib maleate. One supplier is listed for this compound. Additional details are available on the glasdegib maleate profile page.
Summary for DAURISMO
| International Patents: | 49 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 40 |
| Patent Applications: | 5 |
| Drug Prices: | Drug price information for DAURISMO |
| DailyMed Link: | DAURISMO at DailyMed |
Generic Entry Opportunity Date for DAURISMO
Generic Entry Date for DAURISMO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for DAURISMO
| Drug Class | Hedgehog Pathway Inhibitor |
| Mechanism of Action | Smoothened Receptor Antagonists |
US Patents and Regulatory Information for DAURISMO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-002 | Nov 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-002 | Nov 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DAURISMO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2010531869 | Start Trial |
| European Patent Office | 2170860 | Start Trial |
| Spain | 2609258 | Start Trial |
| Canada | 2690953 | Start Trial |
| Argentina | 103632 | Start Trial |
| Japan | 4567099 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
